The most useful questions to ask before NAD+ cover your goal, the evidence, your health history and what follow-up would look like. Medicines, supplements, pregnancy, cancer history and previous reactions all belong in that conversation. A visit needs a clear reason to consider treatment and a plan for judging it.
NAD+ stands for nicotinamide adenine dinucleotide, a helper molecule cells use for energy and repair. Being essential inside cells doesn't establish what giving extra NAD+ does for a person. These ten questions explain what the provider needs to know, and why.
The broader decision is covered in whether NAD+ fits your situation.
Questions to ask before NAD+: goals and evidence
1. What am I hoping to change, and why now?
The provider wants a specific goal, when the problem began and what has already been investigated or tried. “More energy” means different things: staying awake at work, recovering after activity or getting through ordinary tasks. The history helps make the treatment question concrete.
As of October 1, 2026, the day this article was written, a September 8 analysis by Gao and colleagues in Frontiers in Nutrition found no significant improvement in reported tiredness from the tested NAD-related supplements. Those findings concern supplements, rather than NAD+ injections. A plausible cell mechanism isn't enough to promise relief from tiredness.
2. What human evidence matches the proposed treatment?
The review needs to distinguish the molecule, how it is given and what researchers measured. In Grant's 2019 pilot in Frontiers in Aging Neuroscience, eight men received NAD+ over six hours; three received saline, saltwater. IV means delivery into a vein. Researchers tracked blood and urine chemicals, rather than energy or aging benefits.
Measured NAD+ in plasma, the liquid part of blood, did not rise during the first two hours. That does not mean NAD+ was absent from blood.
The NAD+ injection overview and IV study walkthrough explain those evidence limits.
Promise offers NAD+ by prescription, after a licensed provider reviews your request; it is a compounded injectable medication, prepared by a pharmacy for a prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not verify compounded drugs' safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
Medicines, supplements and heart history
3. How do my medicines and supplements affect the review?
The provider needs names, amounts and recent changes, including nonprescription products. NR, nicotinamide riboside, and NMN, nicotinamide mononucleotide, are precursors: ingredients the body uses to make NAD+. Niacin is vitamin B3. These related products aren't interchangeable.
The NIH niacin fact sheet explains that nicotinic acid, one form of niacin, can cause flushing, meaning skin warmth and redness. Nicotinamide, another form, does not cause that flushing. Knowing the exact supplement helps interpret a previous reaction. The early injection study discussed below excluded existing NAD-related supplement use, so it cannot establish the safety of combining them.
4. What does my heart or blood-pressure history change?
The review includes heart disease, an irregular heartbeat, blood-pressure problems and any previous chest symptoms. These details matter when a treatment can produce symptoms that overlap with an existing condition.
In Reyna's 2026 records review in Frontiers in Aging, all six NAD+ IV clients reported symptoms including nausea, a faster heart rate and chest pressure during infusions. Symptoms stopped when the infusions ended. That small study doesn't establish that a new chest symptom is harmless. The NAD+ side-effects guide covers the reported reactions.
Pregnancy and cancer history
5. What does pregnancy, trying to conceive or breastfeeding change?
These details matter because the small human studies don't establish safety for a pregnant person or a nursing baby. NAD+'s natural presence in the body doesn't answer the question about extra exposure.
An injection pilot posted April 30, 2026 excluded pregnancy, attempts to conceive and breastfeeding. It is a preprint, a report shared before a journal's independent expert review. Results from the enrolled adults cannot establish safety during pregnancy or breastfeeding. The provider weighs that missing evidence as part of the review.
6. Why does a current or past cancer diagnosis matter?
The provider needs the cancer type, treatment history and any ongoing cancer care. The concern comes from NAD+'s role in cell growth and repair, rather than proof that NAD+ injections cause cancer.
Chiarugi and colleagues' 2012 review in Nature Reviews Cancer describes how cancer cells depend on NAD metabolism, the processes that make and use NAD. That biology explains why researchers study it as a cancer-treatment target. It doesn't establish the effect of prescribed NAD+ in someone with cancer. The unresolved question belongs in discussion with the cancer-care team.
Organ function and previous reactions
7. Do my kidney or liver problems change the evidence?
The review includes known kidney or liver disease and relevant previous blood-test results. These organs help process and clear substances, so their function is part of understanding an exposure.
Grant's IV pilot excluded people with a history of liver or kidney failure. Its short observation period and selected participants can't establish safety for someone with those conditions. A reassuring blood test in a small study isn't clearance for every medical history.
8. How would previous injection or IV reactions be assessed?
The provider wants the product, what happened, how quickly it began and what care was needed. Warmth, nausea, a rash and severe shaking are different histories, even when all get called “a reaction.”
FDA's notice dated October 30, 2024 described severe chills, shaking, vomiting and fatigue after injectable NAD+. The reports were consistent with excessive endotoxin, bacterial residue that can trigger illness. The agency also identified food-grade NAD+ used for IV products. A past reaction may involve the preparation or delivery as well as the molecule.
Who handles preparation and monitoring?
9. Who prepares the medication, and who handles a problem?
The visit needs to identify the dispensing pharmacy, the labeled ingredients, the lot number and the contact for unwanted effects. Keeping a preparation free of germs and harmful bacterial residue is a different question from whether NAD+ has a hoped-for benefit.
For an IV, placing and monitoring the line adds another responsibility. The NAD+ IV death report describes a reported medical-examiner finding of air entering the IV line, rather than a toxic effect of NAD+. That distinction explains why the provider's training and the monitoring arrangements matter alongside the pharmacy's work.
Progress, follow-up and stopping
10. What would count as progress, and when would we stop?
The conversation needs a starting measure, a follow-up date and a plan for new symptoms or no meaningful improvement. A particular daily task or a consistent tiredness score gives the provider something clearer than “feeling younger.”
As of October 1, 2026, the day this article was written, Igarashi's September 25 trial in npj Aging adds a useful distinction. It assigned 62 adults aged 65 or older to oral NMN or placebo, a comparison without the active ingredient, for 24 weeks. Blood NAD+ rose without significant improvement in hearing or physical performance. This tested oral NMN, rather than NAD+ injections.
A higher blood number and a helpful change in daily life are different outcomes. Follow-up gives the provider a way to reassess the original goal and decide whether continuing makes sense.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
